Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study

• Published in: Journal of bio-X research Vol. 4; no. 2; pp. 53 - 59
• Main Authors: Fan, Song, Zhen, Qi, Chen, Cheng, Wang, Wenjun, Wu, Qibing, Ma, Huihui, Zhang, Chengyuan, Zhang, Li, Lu, Baojing, Ge, Huiyao, Yong, Liang, Li, Bao, Yu, Yafen, Chen, Weiwei, Mao, Yiwen, Qu, Guangbo, Su, Li, Wang, Aoli, Ding, Zhen, Li, Haiwen, Zhang, Jin, Wang, Yonglian, Gao, Yufeng, Xu, Xihai, Zhu, Zhongming, Chen, Jun, Zhang, Long, Liang, Hongqiang, Wu, Song, Huang, Meng, Xia, Quan, Li, Ping, Sun, Yehuan, Liang, Chaozhao, Wei, Wei, Liu, Qingsong, Sun, Liangdan
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01.06.2021; American Association for the Advancement of Science (AAAS)
• Subjects: COVID-19; real-world study; arbidol; emetine; randomized controlled clinical trial
• ISSN: 2096-5672; 2577-3585
• DOI: 10.1097/JBR.0000000000000076

Emetine, an isoquinoline alkaloid that is enriched at high concentrations in the lung, has shown potent in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to better understand the effectiveness of low-dose emetine for patients with coronavirus disease 2019 (COVID-19). In this real-world study, 63 patients with mild or common COVID-19 were recruited from Wuhan Fangcang Shelter Hospital and five COVID-19-designated hospitals in Anhui Province, China from February to March 2020. Thirty-nine patients from Wuhan Fangcang Shelter Hospital were assigned to a pragmatic randomized controlled clinical trial, and 24 patients from the 5 COVID-19-designated hospitals in Anhui Province underwent a real-world study. The medication course of emetine was less than 10 days. The main symptoms and adverse reactions of all patients were observed and recorded. The primary outcome measure was the time required for a negative SARS-CoV-2 RNA result or the negative result rate on day 10. Secondary outcomes included axillary temperature, transcutaneous oxygen saturation, and respiratory frequency recovery. The study was approved by the Ethics Committee of The First Affiliated Hospital of Anhui Medical University on February 20, 2019 (approval No. PJ2020-03-19) and was registered with the Chinese Clinical Trial Registry on February 20, 2019 (registration number: ChiCTR2000030022). The oxygen saturation values were higher in the treatment group than in the control group on the first day after enrollment for patients treated at Fangcang Shelter Hospital. The axillary body temperature, respiratory rate, and oxygen saturation among patients in Fangcang Shelter Hospital were related to the time effect but not to the intervention measures. The respiratory rate and oxygen saturation of patients in the Anhui designated hospitals were related to the intervention measures but not to the time effect. The axillary body temperature of patients in Anhui designated hospitals was related to the time effect but not to the intervention measures. Our preliminary study shows that low-dose emetine combined with basic conventional antiviral drugs improves clinical symptoms in patients with mild and common COVID-19 without apparent adverse effects, suggesting that moderately increased doses of emetine may have good potential for treatment and prevention of COVID-19.